Yarrow Bioscience, Inc. ·
YARW 8-K 2026-11-12
Yarrow Bioscience, Inc. (YARW) 8-K dated 2026-11-12 — accession 0001566044-26-000017.
Yarrow Bioscience, Inc. (YARW) common stock.
VYNE: Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Prov…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported YARW revenue for 2025-12-31 was $570.0K. Net income was -$26.5M. Revenue was up 13.8% from 2024-12-31 to 2025-12-31. YARW currently screens at market cap $52.4M.
Not investment advice. The YARW SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects its cash and cash equivalents to fund operations into 2030, including through the completion of the DIRECTION-GD trial
Why it matters
- expects its cash and cash equivalents to fund operations into 2030, including through the completion of the DIRECTION-GD trial